We are live on ! Find out more
TS

Thomas Steyer Farallon Capital Management

AUM $21.7B
1-Year Est. Return 79.24%
 

Thomas Steyer founded Farallon Capital Management, a pioneering multi-strategy firm spanning credit, equities, real estate, and event-driven investing. Farallon became known for rigorous research and opportunistic capital allocation across cycles. Although Steyer later focused on public advocacy, the Farallon name remains important in hedge fund history and ongoing 13F tracking.

This Fund
S&P 500
This Quarter Est. Return
+13.5%
1 Year Est. Return
+79.24%
3 Year Est. Return
+204.51%
5 Year Est. Return
+270.91%
10 Year Est. Return
+1,884.18%
AUM
$21.9B
AUM Growth
+$430M
Cap. Flow
-$2.03B
Cap. Flow %
-9.27%
Top 10 Hldgs %
51.69%
Holding
190
New
27
Increased
30
Reduced
39
Closed
32

Top Buys

Rank Stock Value
1
PXD
Pioneer Natural Resource Co.
PXD
+$731M
2
HES
Hess
HES
+$436M
3
NDAQ icon
Nasdaq
NDAQ
+$341M
4
SPLK
Splunk Inc
SPLK
+$157M
5
UTHR icon
United Therapeutics
UTHR
+$110M

Top Sells

Rank Stock Value
1
ATVI
Activision Blizzard
ATVI
+$1.9B
2
VMW
VMware, Inc
VMW
+$915M
3
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$770M
4
SGEN
Seagen Inc. Common Stock
SGEN
+$482M
5
AON icon
Aon
AON
+$216M

Sector Composition

Rank Sector Weight
1 Healthcare 27.49%
2 Technology 11.1%
3 Financials 9.67%
4 Industrials 6.16%
5 Communication Services 5.57%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LBPH
76
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
$9.41M 0.04%
1,560,500
– –
SOVO
77
DELISTED
Sovos Brands, Inc. Common Stock
SOVO
$9.21M 0.04%
+418,000
New +$9.19M
CZOO
78
DELISTED
Cazoo Group Ltd
CZOO
$6.79M 0.03%
+714,240
New +$24.6M
SLNO
79
DELISTED
Soleno Therapeutics
SLNO
$6.65M 0.03%
165,219
-222,781
-57% -$6.34M
HCA icon
80
HCA Healthcare
HCA
$92.9B
$5.66M 0.03%
20,900
-153,500
-88% -$37.9M
GOSS icon
81
Gossamer Bio
GOSS
$75.6M
$5.59M 0.03%
6,130,272
– –
GHIX
82
DELISTED
Gores Holdings IX, Inc. Class A Common Stock
GHIX
$5.25M 0.02%
500,000
– –
VNET
83
VNET Group
VNET
$1.91B
$5.09M 0.02%
1,775,000
– –
QTRX icon
84
Quanterix
QTRX
$141M
$5.03M 0.02%
+184,000
New +$4.33M
IOVA icon
85
Iovance Biotherapeutics
IOVA
$3.76B
$4.57M 0.02%
+562,000
New +$2.94M
CRNX icon
86
Crinetics Pharmaceuticals
CRNX
$8.99B
$4.37M 0.02%
122,904
-239,000
-66% -$7.33M
IVCP
87
DELISTED
Swiftmerge Acquisition Corp. Class A Ordinary Share
IVCP
$3.23M 0.01%
300,000
– –
BACA
88
DELISTED
Berenson Acquisition Corp. I
BACA
$2.93M 0.01%
285,715
– –
BLUE
89
DELISTED
bluebird bio
BLUE
$2.76M 0.01%
+100,000
New +$6.1M
ARYD
90
DELISTED
ARYA Sciences Acquisition Corp IV Class A Odinary Shares
ARYD
$2.18M 0.01%
200,000
– –
MTAL
91
DELISTED
Metals Acquisition
MTAL
$1.95M 0.01%
157,500
– –
GATE
92
DELISTED
Marblegate Acquisition Corp. Class A Common Stock
GATE
$1.56M 0.01%
150,000
– –
FBRX icon
93
Forte Biosciences
FBRX
$1.63B
$1.49M 0.01%
72,418
– –
MTAL.WS
94
DELISTED
Metals Acquisition Limited Warrants to purchase one share of Ordinary Share, each at an exercise price of $11.50 per share
MTAL.WS
$1.41M 0.01%
825,000
– –
TVRD
95
Tvardi Therapeutics
TVRD
$24.8M
$1.16M 0.01%
43,229
-3,065
-7% -$127K
SMC
96
Summit Midstream
SMC
$470M
$1.04M ﹤0.01%
58,214
– –
GRND.WS
97
DELISTED
Grindr Inc. Warrants, each exercisable for one share of Common Stock at an exercise price of $11.50 per share
GRND.WS
$977K ﹤0.01%
540,000
– –
EDU icon
98
New Oriental
EDU
$8.88B
$953K ﹤0.01%
13,000
– –
SAGE
99
DELISTED
Sage Therapeutics
SAGE
$927K ﹤0.01%
42,800
– –
MDGL icon
100
Madrigal Pharmaceuticals
MDGL
$11.9B
$768K ﹤0.01%
3,319
– –
2 3
4
5 6

Similar funds

BG
Bahl & Gaynor Cincinnati, Ohio $21.7B AUM 30.58% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.7B AUM 77.3% 1-Year Est. Return
OSAM
O'Shaughnessy Asset Management Stamford, Connecticut $21.7B AUM 41.93% 1-Year Est. Return
SA
Sanctuary Advisors Indianapolis, Indiana $21.6B AUM 28.31% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $21.5B AUM 23.65% 1-Year Est. Return
CHP
Castle Hook Partners New York $21.8B AUM 215.45% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
ETC
Exchange Traded Concepts Oklahoma City, Oklahoma $21.9B AUM 68.6% 1-Year Est. Return

Thomas Steyer's Q4 2023 Portfolio in Review

As of Q4 2023, Thomas Steyer held 190 positions worth $21.9B, up 2% from $21.4B the previous quarter. Its ten largest holdings account for 52% of the portfolio.

Thomas Steyer withdrew a net $2.03B in Q4 2023, closing 32 positions and reducing 39 holdings. Its most notable exit was Activision Blizzard, an estimated $1.9B position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 27% of assets, down from 31% a quarter earlier, followed by Technology and Financials.

Against the trend, Thomas Steyer opened a new position in Pioneer Natural Resource Co. worth $702M.

  • Thomas Steyer's largest Q4 2023 buy was Pioneer Natural Resource Co.: 3,120,000 shares worth $702M.
  • Thomas Steyer added most to Nasdaq in Q4 2023, an estimated $341M increase.
  • Thomas Steyer's biggest Q4 2023 reduction was AstraZeneca, cutting an estimated $145M.
  • Thomas Steyer fully exited Activision Blizzard in Q4 2023, selling an estimated $1.9B.
  • Thomas Steyer's ten largest holdings make up 52% of its $21.9B portfolio in Q4 2023.
  • Thomas Steyer opened 27 new positions and closed 32 in Q4 2023.
  • Thomas Steyer's portfolio value rose 2% quarter-over-quarter to $21.9B.

Based on Farallon Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.